Latest News

Blue Note Therapeutics Partnering with Patient Advocacy Groups to Provide Digital Cancer-Related Mental Health Care During Pandemic

January 2021

Blue Note Therapeutics' 2020 year-end wrap-up.

Read more →

Blue Note Therapeutics Enters Licensing Agreement with Massachusetts General Hospital for Digital Therapeutic for Acute Myeloid Leukemia Patients

October 2020

Blue Note prepares to advance development of online mental health treatment for those with AML.

Read more →

Blue Note Therapeutics Enters Agreement to Create a Prescription Digital Therapeutic Medical Device for Cancer Patients

September 2020

Memorial Sloan Kettering Cancer Center (MSK) and Blue Note Therapeutics, Inc. have agreed to collaborate on creating a prescription digital therapeutic medical device from a psychological intervention created specifically for cancer patients with advanced cancer.

Read more →

Blue Note Therapeutics Receives Breakthrough Device Designation from FDA for Prescription Digital Therapeutic to Treat Cancer-Related Anxiety and Depression

June 2020

Blue Note Therapeutics, Inc. announced that the U.S. FDA has granted Breakthrough Device Designation to BNT001, the company’s lead prescription digital therapeutic (PDT) candidate.

Read more →

Blue Note Therapeutics Enters Licensing Agreement with the University of Miami

May 2020

The agreement allows Blue Note to develop and commercialize a prescription digital therapeutic for stress management in cancer patients.

Read more →